Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease
Clinical trial NCT02023866 · COMPLETED
Trial details
- NCT number
- NCT02023866
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-01
- Primary completion
- 2016-10-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.